**HRAS** germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models

Laetitia Dard, … , Didier Lacombe, Rodrigue Rossignol

*J Clin Invest.* 2022;132(8):e131053. https://doi.org/10.1172/JCI131053.

**Graphical abstract**

Find the latest version:

https://jci.me/131053/pdf
Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators.

Related Commentary: https://doi.org/10.1172/JCI117560

Conflict of Interest: RR, DL, LD, and NDA report a patent (PCT/EP2022/051382) on the use of the bezafibrate and urolithin A pharmacological drug combination for the treatment of hypertrophic cardiomyopathy in Costello syndrome.

Copyright: © 2022, Dard et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: June 13, 2019; Accepted: February 23, 2022; Published: April 15, 2022.

Reference Information: J Clin Invest. 2022;132(8):e131053. https://doi.org/10.1172/JCI131053.
ylation (OXPHOS) (15) as well as on the partial overlap of clinical manifestations between mitochondrial diseases and RASopathies (16). The central role of mitochondrial dysfunction in HCM pathophysiology was also demonstrated in vivo using transgenic mice, with the following KOs: Prkca2 (17), Ppargc1a (18, 19), Nfe2l2 (20), Esrra (21), Ppara (22), Clpp (23) or Yme1l1 (24).

In the present study, we explored the bioenergetics of the heart and skeletal muscle in different cell and animal models of CS and discovered alteration in the molecular control of mitochondrial proteostasis. We tested the effect of mitochondrial turnover and bioenergetics pharmacological stimulation on HCM prevention at the preclinical stage in the CS mouse and zebrafish models.

Results
Patients with CS and a mouse model exhibit left ventricular HCM.
First, we regrouped a cohort of 10 patients with CS (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI131053DS1) to investigate heart structure and function. Echocardiography revealed a characteristic left ventricular hypertrophy in 70% of the patients (Supplemental Figure 1, A-D). Electrocardiograms obtained of patients with CS further revealed that 50% of the patients had abnormal deviation of the heart axis (Supplemental Table 2). Two patients had a right deviation of the electrical axis with discrete echocardiographic left ventricular hypertrophy. Furthermore, pathologic Q waves were present in 40% of patients, and all patients with pathologic Q waves had only discrete ventricular hypertrophy on echocardiography. In the heterozygous HRAS p.G12S mouse model of CS, we observed increased left ventricle volume (Figure 1, A-F, and Supplemental Figure 1, F and G) and cardiomegaly (Supplemental Figure 1E and Supplemental Figure 2). A significant increase in systolic arterial blood pressure was also observed in these animals at 8 and 20 weeks of age (Supplemental Figure 1H) without alteration in heart beating rate (Supplemental Figure 1I). Likewise, hypertension was observed in all the patients with CS considered in this study (Supplemental Table 1). Further evaluation of the heart structure and function by echocardiography confirmed the increase in left ventricle volume at diastole and systole (Figure 1, E and F). Evaluation of the left ventricular diastolic function, including early and late mitral flow E wave velocities revealed a significant increase in these 2 parameters in 23-week-old CS mice (Figure 1, I-K). These findings might reflect increased left atrial filling pressures in the left atrium. The E wave velocity through the tricuspid valve was also increased (Figure 1, L-N), suggesting occurrence of tricuspid regurgitation. Tricuspid regurgitation, in combination with left ventricular dysfunction was associated with excess mortality in previous studies (25). Last, the pulmonary vein peak velocity was also reduced in 23-week-old CS mice (Figure 1G). Comparison of the echocardiography studies performed at 11 and 23 weeks of age showed that the cardiac disease was progressive and did not reach yet the state of heart failure, as the ejection fraction and the E/A ratio remained unaltered (Figure 1, H and K, and Supplemental Figure 3). Nevertheless, the descending aorta peak velocity was significantly reduced in the CS mouse heart (Figure 1, O and P), and the establishment of a ventricular dilation (Figure 1, A and F) with altered mitral and tricuspid flow E wave velocities (Figure 1, I, J, and L-N) was significant in the CS mouse model. These observations indicate that left ventricular cardiac hypertrophy is a characteristic feature of CS in most patients and in the HRAS p.G12S mouse model.

The CS mouse model exhibits heart and skeletal muscle bioenergetic dysfunction. Mitochondrial dysfunction is an important determinant of HCM (26); thus, we investigated heart bioenergetics in the CS mouse model. The in situ evaluation of OXPHOS (Figure 2A) was performed in heart-permeabilized muscle fibers obtained from control or heterozygous 12-week-old CS mice. This analysis revealed a reduced rate of coupled respiration (state 3) associated with a decreased rate of ATP synthesis (Figure 2, B-D). Measurement of the respiratory chain complex enzymatic activity (Figure 2, E and F) demonstrated a generalized decrease in complex I-IV activity in the CS mouse heart (Figure 2E). Respiratory chain complex enzymatic activity defects were also discovered in the skeletal muscle of CS mice (Figure 2F). Furthermore, histo-enzymology determination of complex IV activity in the skeletal muscle showed a strong reduction in the number of COX-positive fibers (Figure 2, G and H). Accordingly, a reduction of state 3 respiration and mitochondrial ATP synthesis were observed in permeabilized skeletal muscle fibers obtained from 12-week-old heterozygous CS mice (Supplemental Figure 3). These findings revealed the existence of mitochondrial dysfunction in both the myocardium and skeletal muscle of CS mice.

Mitochondrial proteostasis is altered in CS. To unravel the molecular mechanisms underpinning early OXPHOS dysfunction in the CS mouse model we performed a label-free proteomic analysis (Figure 3A) of (a) 4 CS mouse tissues (skeletal muscle, heart, liver, and brain) obtained at 3 and 12 weeks of age from homo- and heterozygous HRAS p.G12S animals, (b) human primary skin fibroblasts obtained from 3 patients with CS carrying HRAS p.G12S or HRAS p.G12A mutations, and (c) human primary skin fibroblasts expressing ectopic HRAS p.G12S or HRAS p.G12A lentiviral constructs (n = 4 clones for each construct). Comprehensive analysis of the cellular biochemical processes altered by mutant HRAS (Figure 3B) consistently identified “mitochondrial dysfunction” and “OXPHOS” with the highest score (−log(P value)) in each of the CS models, suggesting a generalized alteration of the mitochondrial proteome homeostasis consecutive to germline and somatic HRAS mutation. However, the direction of the changes observed in the content of selected mitochondrial proteins varied between tissues. For instance, a predominant decrease of OXPHOS components was detected in the heart and liver, while a dominating accumulation of these proteins was observed in the muscle, brain, and skin fibroblasts from patients with CS as well as in the related mutated HRAS p.G12S– and p.G12A–expressing cell models (Figure 3C). A focus on the common molecular changes that occurred in the hearts and livers, 2 tissues with very different functions, of 3-week-old heterozygous and homozygous CS mice revealed a reduction of fatty acid oxidation enzymes and 5’ AMP-activated protein kinase (AMPK) indirect transcriptomic targets (Figure 3, D and E). These findings raised the hypothesis that HRAS p.G12S mutation could trigger alteration of mitochondrial proteome homeostasis with a more pronounced effect on mitochondrial biogenesis or degradation according to the tissue considered and stage of development. Given the role of the LKB1/AMPK signaling axis in the tissue-specific control of mitochondri-
The accumulation of mitochondrial proteins (Figure 3C) suggested a decreased AMPKα expression in cells from patients with CS, the observed 2 and LKB1 protein content were substantially as the AMPK

1+ prolysis was low in our experimental conditions (Supplemental Figure 6). This analysis revealed that AMPK, CRIF1, and SQSTM1/p62 were consistently reduced both in CS mouse heart and in skin fibroblasts from patients with CS. Previous work has already shown that AMPK, CLPX, ATG7, CRIF1, and SQSTM1/p62 inhibition trigger defective mitochondrial proteostasis, cellular bioenergetics impairment, and inhibition of the autophagic flux (27-30). Accordingly we measured a defective mitochondrial bioenergetics (Figure 2, B-D) and decreased autophagic flux (Figure 4, L-N) in the different CS cell models. The mitochondrial proteostasis regulator CLPX, which was downregulated in CS cells, had previously been identified as a transcriptomic target of AMPK and PGC1α (31,32), 2 large-scale transcriptional regulators strongly downregulated in CS cells.

Mitochondrial biogenesis, the second arm of mitochondrial turnover controlled by AMPK, was evaluated by measuring the expression level of TFAM in cells from patients with CS using Q-PCR (Figure 4O). TFAM content was decreased in cells from patients with CS (as well as in CS mouse heart; Supplemental Figure 5), in line with an alteration of mitochondrial biogenesis. These findings indicate that the LKB1/AMPK signaling axis is altered in cells from patients with CS and CS mouse hearts and that mitochondrial biogenesis and degradation processes are also impaired in these cells. However, the proteomic investigation of CS mouse hearts revealed additional changes in proteins specifically involved in the pathophysiology of cardiomyopathy (Supplemental Figure 7), such as CRYAB, TNN, and MYBP3, suggesting that LKB1/AMPK signaling deregulation is only one mechanism contributing to the complexity of CS heart pathophysiology, as expected in a condition of HRAS/MAPK pathway overactivation. Moreover, comparative analysis of 4 CS mouse tissues taken at 3 weeks of age suggested that alteration of mitochondrial proteostasis in CS mice is tissue specific (Supplemental Figure 8).

miR-221* inhibits AMPKα2 expression in mutant HRAS-expressing cells. Parcellar evidence suggested the existence of a RAS/miR-221* AMPK regulatory axis in human cancer cells (33-36). Moreover, miR-221* overexpression was observed in patients with cardiac hypertrophy after sudden death (37), as can occur in patients with CS. Thus, we evaluated the implication of this pathway in CS pathophysiology using different approaches. First, in silico analysis of the differential proteomics data obtained in skin fibroblasts from patients with CS and in mutant HRAS-expressing cells showed that a common core of 71 proteins downregulated by germline HRAS mutation were predicted targets of miR-221* (Supplemental Figure 9, A and B). These proteins play a role in cellular functions, such as cell migration, cell proliferation, and cell adhesion (Supplemental Figure 9, C and D). Moreover, miR-221* expression was increased in fibroblasts from patients with CS and in human fibroblasts expressing ectopic mutant forms of
Figure 2. Mitochondrial bioenergetics is altered in situ in the CS mouse heart and skeletal muscle. (A) Permeabilized heart muscle fibers bioenergetics evaluation methods. (B) Rate of coupled (ADP-stimulated “state 3”) respiration was determined in situ using high-resolution respirometry (WT, n = 6; Costello, n = 9). (C and D) Rate of mitochondrial ATP synthesis (vATP) determined in heart-permeabilized muscle fibers (WT, n = 5; Costello, n = 6). (E) Electron transport chain (ETC) complex enzymatic activities determined in WT or Costello mouse model hearts (WT, n = 4; Costello, n = 4). (F) Respiratory chain complex enzymatic activities determined in WT or Costello mouse model skeletal muscle (WT, n = 4; Costello, n = 4). (G) Histo-enzymology staining of the respiratory chain complex IV (COX) specific activity. Muscle fibers and their nuclei were stained using H&E. Original magnification, ×1000. (H) Quantification of the COX-positive muscle fibers (WT, n = 3; Costello, n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t test).
HRAS (Figure 5A), in agreement with our hypothesis (Figure 5B). Furthermore, inhibition of miR-221* expression using a specific anti-miR rescued the expression of AMPKα2 protein, mRNA, and activity in HRAS p.G12S– or HRAS p.G12A–expressing cells (Figure 5, C–E). The rescuing effect of anti–miR-221* was also found at the level of AMPK and PGC1α expression, mitochondrial respiration, and mitochondrial ATP levels in both cells from patients with CS and mutant HRAS cell models (Figure 5, E–G). A different sensitivity to the anti–miR-221* was observed between the HRAS p.G12S– and the HRAS p.G12A–expressing fibroblasts (Figure 5C). In the former cell line the increase in total AMPK content was strong, while in the latter it was weak. Still, in the 2 cell lines expressing mutant forms of HRAS, the anti–miR-221* triggered a marked increase in the pThr172/AMPK total AMPK ratio. In contrast, the miR-221*-mimic altered cell respiration in control fibroblasts. The number of mitochondrial particles was also increased in cells from patients with CS and in mutant HRAS cell models treated with the anti–miR-221* (Figure 5, H and I). Finally, antimiR-221* stimulated cell growth in glucose-deprived media that forced cells to rely on OXPHOS (38) for survival (Supplemental Figure 10). Taken together, these findings indicate that HRAS p.G12A and p.G12S activate the expression of miR-221* but also that miR-221* inhibits the expression and function of AMPKα2 in skin fibroblasts derived from patients with CS and related cellular models. Our findings also demonstrate that both AMPK phosphorylation status (thr172) and mitochondrial biogenesis can be rescued in vitro using an anti–miR-221*. However, we could not detect the endogenous level of miR-221* in the WT and the CS mouse heart, indicating that inhibition of AMPKα2 by miR-221* may occur by different mechanisms in this tissue. The reduced expression of LKB1 found in the CS mouse heart (Figure 4J), as also observed in skin fibroblasts from patients with CS (Figure 4I), provides an additional mechanism responsible for the inhibition of LKB1/AMPK signaling in CS.

**Mitochondrial proteostasis modulators restore organelle homeostasis in CS cell and animal models.** The above-described findings suggested the evaluation of a preclinical therapeutic strategy in CS based on the stimulation of mitochondrial protein biogenesis and quality control. Bezafibrate (BZ) was selected to reach this goal, because this drug could stimulate mitochondrial bioenergetics in previous studies (39–44). Accordingly, we observed that BZ increased the expression of the PGC1α 100 KDa form, raised the level of TFAM, and reduced activation of the mTOR pathway (Figure 7A). The enzymatic activity of respiratory chain complexes was also increased by a glycolytic compensatory response (HRAS p.G12S). These data indicate that most of the ATP produced in CS hiPSC-CMs was obtained from glycolysis, as OXPHOS inhibition with oligomycin, antimycin A, and rotenone did not entail a drop in the cellular ATP level. As a result, CS hiPSC-CM viability was reduced in a strictly oxidative cell growth medium (Figure 6H). Finally, we observed a reduction of respiratory chain protein content in these cells (Figure 6D) as well as a decreased p Thr172/AMPK level (Figure 6J). No difference in AMPKα1+2 was detected between the CS cardiomyocytes and the WT hiPSC-CMs, and the level of p Thr172/AMPK was very low in the 2 groups. These findings indicate that the defective mitochondrial bioenergetics phenotype discovered in CS mouse heart and skin fibroblasts from patients with CS was also present in human cardiomyocytes derived from hiPSCs from patients with CS.
with 500 μM BZ rescued mitochondrial proteome homeostasis and organelle function in vitro (Figure 7, C-F).

Thus, we performed preclinical treatment of the CS mouse model with BZ 0.05% (Figure 7G). After 12 weeks of treatment with BZ 0.05% in the diet, the enzymatic activity of respiratory chain complex I, complex IV, and citrate synthase was increased (Figure 7G). Moreover, the echocardiography analysis of the treated CS mice revealed that the left ventricle volume was specifically reduced by this treatment (Figure 7, H and I). No significant change was observed in the total mass of the heart (Figure 7J). A substantial reduction of the heart-beating rate was also obtained by the treatment, without modification of the systolic arterial pressure (Figure 7, K and L). Altogether, these findings suggest that the BZ 0.05% treatment prevented development of the left ventricle hypertrophy in the CS mouse model and normalized the heart-beating rate. Still, more specific cardiac functional assessments for reversal/prevention of HCM in CS will need to be performed to prove the therapeutic possibility of using BZ for treating the cardiac disease in CS.

CS is a developmental disorder, so we tested the preclinical strategy of mitochondrial stimulation at an early stage of the disease. To this aim, we generated a GFP-HRASV12 zebrafish model of CS (Figure 8), as previously described (45). Embryos were observed daily from 2 days post fertilization (dpf) to 5 dpf in order to analyze the effect of HRASV12 overexpression on physiological development (Figure 8, A-G). At 2 dpf, 22% of the HRAS p.G12V embryos died, and this rate increased to reach 60% mortality at 5 dpf (Figure 8H). At 5 dpf, among embryos that were alive, 60% presented developmental defects similar to those observed in humans and mice (Figure 8, G and I) as previously described (45). We observed a cardiac phenotype characterized by heart hypertrophy (12%) and cardiomyopathy (12%) associated with poorly developed heart and reduced blood flow (12%). Additional phenotypes were observed, including brain hemorrhage (6%) and vascularization defect leading to edema in the duct of Cuvier or malformation of the aorta or the vein in the tail region around the urogenital opening (12%). The interindividual variability observed within the CS zebrafish population could be explained by the genetic position effect of the HRAS p.G12V transgene, as controlled by the regulatory environment of the genomic integration sites. In order to analyze the effect of mitochondrial bioenergetics and organelle proteostasis modulators on the potential rescue of the observed HRAS p.G12V embryo developmental phenotype, BZ and/or ursothiolin A (UA) were added to the zebrafish medium (Figure 8, C-F). Animal phenotyping revealed that the BZ and UA treatments increased the survival rate up to 70% and 65% (Figure 8H), respectively, and decreased the number of defective embryos among alive embryos (45% and 43%, respectively) as compared with the vehicle-treated (DMSO) HRAS p.G12V embryos (60% of defective embryos; Figure 8, F and I). The combination of 10 μM BZ and 5 μM UA increased substantially the treatment efficiency by improving embryo survival up to +30% (Figure 8H) and reduced to a large extent (3-fold) the number of animals presenting genetic developmental defects (Figure 8, F and G), as compared with vehicle-treated embryos. Measurement of HRASV12 plasmid expression by analysis of the level of GFP fluorescence expression confirmed the stable expression of the transgene during the experiments and the absence of effect of the different treatments on the HRASV12 plasmid expression (Supplemental Figure 14A). Finally, molecular investigation of the CS zebrafish model using Western blot performed on whole embryos revealed a 2-fold reduced expression of the mitochondrial marker TOM20 (Figure 8J). The combination treatment composed of 10 μM BZ and 5 μM UA restored the expression level of TOM20 in the whole embryo and corrected the defective phenotype (Figure 8, F and I, and Supplemental Figure 14B). A proteomic study performed on whole zebrafish animals treated with 10 μM BZ and 5 μM UA (Supplemental Figures 15 and 16) revealed a mode of action composed of at least 3 molecular mechanisms. (a) Bioenergetic stimulation, consisting of a strong stimulation of fatty acid oxidation systems (very-long-chain 3-oxoacyl-CoA reductase-A, carnitine O-palmitoyltransferase, electron transfer flavoprotein subunit β, etc.), suggested the occurrence of an “oxidative shift.” Accordingly, the LXR/RXR pathway that controls fatty acid metabolism was activated by the treatment (Supplemental Figure 16B). (b) Proteostasis modulation, consisting of stimulation of mitochondrial proteostasis machinery, included upregulation of Hsp70, CLPP, YME1-like 1b, COX7A2, ubiquinol-cytochrome c reductase complex assembly factor 1, and DNAJ (Hsp40 cochaperone) as well as selected proteasome components. The 2 proteases CLPP and YME1L1 have a particular interest in our study, as their genetic inhibition induces cardiomyopathy (23, 24). (c) Activation of the acute-phase response signaling pathway shows a systemic response aimed at the restoration of tissue homeostasis. In particular, the level of angiotensinogen, the sole precursor of all angiotensin peptides, was increased by a factor of log₂fold = 4.
The Journal of Clinical Investigation

Figure 5. miR-221-5p inhibits AMPKα2 expression in an HRAS-dependent manner. (A) miR-221-5p (miR-221*) expression in skin fibroblasts from patients with CS and related transgenic cell models (n = 3). (B) Description of the HRAS/miR-221*/AMPK pathway. (C and D) Rescue of AMPKα2 expression by anti-miR-221-5p at the protein and the mRNA levels, respectively (n = 3). (E) Rescue of AMPKα2 expression, T172_P-AMPK/total AMPK ratio, and PGC1α expression by the anti-miR-221-5p (n ≥ 3). (F) Rescue of mitochondrial respiration by anti-miR-221-5p and its inhibition by a miR-221-5p mimic (n ≥ 3). (G) Rescue of mitochondrial steady-state ATP content by the anti-miR-221-5p (n ≥ 3). (H and I) Rescue of mitochondrial particles number by anti-miR-221-5p (n = 3). Original magnification, ×1000. Two-way ANOVA with Dunnett’s correction for multiple testing was used to compare the 3 groups of cells expressing HRAS p.G12A, HRAS p.G12S, or the empty plasmid control (pV) treated with the anti-miR scramble or the anti-miR-221-5p. Unpaired t test was used to compare the 2 groups of cells obtained from patients with CS and controls. Data are expressed as the mean ± SEM.* P < 0.05, ** P < 0.001, **** P < 0.0001.

Discussion

Here, we performed a comprehensive analysis of the molecular determinants of CS using untargeted proteomics, bioenergetics, and molecular biology methods on a collection of biological models: tissues of a HRAS p.G12S CS mouse model, skin fibroblasts from patients with CS, CS hiPSC-CMs, human skin fibroblasts transduced with mutant forms of HRAS p.G12S and HRAS p.G12A, and a HRAS p.G12V zebrafish model of CS. Confrontation of these models allowed us to better understand the molecular impact of mutant HRAS in different contexts and to reveal tissue-specific changes. The original CS mouse model used in our study was generated by a knockin of a mutant HRAS p.G12S gene in C57BL/6 animals and developed HCM. All the CS mouse and zebrafish models reported in the literature develop HCM (7, 10, 16), and this clinical feature can be prognostic of worsening disease for patients.

Using in vitro and in vivo CS biological models, we discovered that germline or somatic HRAS p.G12S and p.G12A mutations alter mitochondrial proteome homeostasis and OXPHOS in a tissue-specific manner. For instance, CS mice exhibited downregulation of OXPHOS components in the heart and the liver, while the brain and, to a lesser extent, the skeletal muscle, showed accumulation of ETC proteins. The CS ectopic cell models (HRAS p.G12A and p.G12S) also exhibited a profile of OXPHOS protein accumulation associated with defective mitochondrial function. We further validated these findings in cardiomyocytes generated from the differentiation of hiPSCs from patients with CS. Taken together, our observations raised the hypothesis of defective mitochondrial homeostasis in CS.

Thus, we investigated the potential implication of AMPK in CS molecular pathophysiology and mitochondrial dysfunction, based on the pathway analysis performed on the differential proteome determined in the different CS mouse tissues and cellular models. Biochemical studies also showed that AMPK controls mitochondrial protein biogenesis and degradation (46, 47). AMPK dysfunction and mitochondrial respiratory chain defects are also frequent causes of HCM (17–22, 48). Our results revealed a strong inhibition of AMPK expression level (mRNA and protein) in heart samples from CS animals, in skin fibroblasts from patients with CS, in cell models overexpressing mutant forms of HRAS, and in CS hiPSC-CMs. These consistent findings support the hypothesis of defective AMPK signaling in CS. The interplay between RAS/ MAPK and AMPK signaling was investigated in previous studies (49) and revealed the inhibition of the latter by the former, by at least 3 mechanisms: (a) LKB1 inhibition, (b) inhibition of AMPK catalytic activity, and (c) inhibition of AMPK by KSR2. However, little is known about the interplay between the HRAS/MAPK and the LKB1/AMPK pathway in the context of RASopathies. Our results revealed the inhibition of PRKAA2 mRNA expression in skin fibroblasts from patients with CS, CS mouse hearts, and hiPSC-CMs. The α2 subunit of AMPK is essential for AMPK signaling because its phosphorylation on Thr172 activates the kinase. Moreover, a reduction of LKB1 protein content was also found in skin fibroblasts from patients with CS and CS mouse hearts, suggesting a dual inhibition of the LKB1/AMPK signaling pathway in CS. The observed reduction of LKB1_Ser428 phosphorylation level in fibroblasts from patients with CS and in CS mouse hearts suggests an even more upstream regulatory mechanism, whereby altered activity of kinases upstream of LKB1 might contribute to the decreased AMPK (thr172) phosphorylation observed. Moreover, LKB1 has numerous phosphorylation sites and the sole change in the phosphorylation level of Ser428 is not sufficient to evaluate LKB1 activity. Alterations in LKB1 interactions with other proteins or changes in its subcellular distribution could also occur.

We also discovered that the inhibition of PRKAA2 mRNA expression by HRAS p.G12S was mediated by microRNA-211-5p (miR-221*). Thus, we searched for a possible effect of miR-221* on PRKAA2 expression in the context of CS. We observed that inhibition of miR-221* rescued cellular energy homeostasis, suggesting that anti–miR-221 strategies could be considered in future studies. However, we were not able to detect the endogenous level of miR-221* in the hearts of WT or CS mice. Technically, the total pool of microRNAs was extracted in sufficient quantity and quality from the CS mouse heart, but amplification of miR-221* with a validated commercially available primer (Qiagen miScript Primer Assay) could not reach the detection threshold. One explanation for this finding could be that the microRNA miR-221-3p is differentially regulated in mouse and human cardiac pathology (50). Moreover, genetic studies investigating the role of miR-221 in the heart made use of transgenic mice overexpressing miR-221, not taking into account endogenous microRNA levels, as we tried to do (51–53). Finally, comparative analysis of microRNAs between humans and mice showed a significant level of divergence in the heart (54). For these reasons, we restrained our explanation of the molecular mechanism responsible for the mitochondrial defective phenotype of CS to the HRAS-mediated inhibition of LKB1/AMPK signaling. However, additional studies will be required to fully understand how altered LKB1 and AMPK signaling and miR-221* increased expression could be responsible for the broad
Figure 6. Mitochondrial bioenergetics is impaired in CS hiPSC-derived cardiomyocytes. (A) Human induced pluripotent stem cells (hiPSCs) were established by electroporation of different primary fibroblasts cell lines. Characterization of the hiPSC-derived cardiomyocytes using cardiac troponin T staining; 2 examples are shown for (B) the control AG08H and (C) the Costello G12S hiPSC-derived cardiomyocytes. Original magnification, ×40. (D) The percentage of Troponin T-positive cells determined using immunocytochemistry is shown for the 4 lineages of hiPSC-derived cardiomyocytes. (E) Expression of the keratin sulfate antigens Tra1-60 and Tra1-81 and the glycolipid antigen SSEA4 was verified by flow cytometry. (F) Determination of AMPKα2 (PRKAA2) mRNA expression level by Q-PCR in hiPSC-derived cardiomyocytes, obtained from 2 patients with CS and 2 controls (n = 3). (G) Measurement of the total cellular steady-state ATP content in hiPSC-derived cardiomyocytes, obtained from 2 patients with CS and 2 controls (n = 3). Evaluation of mitochondrial ATP synthesis was performed using inhibitors of oxidative phosphorylation: antimycin A, oligomycin, and rotenone. (H) Survival of the hiPSC-derived cardiomyocytes, obtained from 2 patients with CS and 2 controls, in an obligatory oxidative growth medium (n = 3). Data are expressed as percentage of the cell number in glucose medium. (I) Western blot evaluation of the expression level of various respiratory chain proteins on hiPSC-derived cardiomyocytes, obtained from 2 patients with CS and 2 controls, using the Oxyphos kit from Abcam. (J) Determination of the protein expression level of AMPK, P-AMPK and P-LKB1. Protein loading was verified using the GAPDH marker. Data are expressed as the mean ± SEM. Unpaired t test was used to compare the 2 groups of hiPSC-CMs (controls and patients). For G, 1-way ANOVA with Dunnett’s correction was used to compare the 3 groups of cells. **P < 0.01, ***P < 0.001.
Figure 7. Bezafibrate rescues mitochondrial bioenergetics and prevents left ventricle cardiac hypertrophy in Costello syndrome. (A) Increased expression of PGC1α, TFAM, and p-70S6K by bezafibrate (500 μM; 48 hours) treatment in skin fibroblasts from patients with CS. (B) CLPXP protein content determined by mass spectrometry of cells from controls, cells from patients with CS, and bezafibrate-treated cells from patients with CS. Quantification was expressed as the normalized peak intensity (n = 3). (C-F) Defective mitochondrial respiration, OXPHOS coupling, mitochondrial transmembrane electric potential, and mitochondrial ATP levels were rescued by bezafibrate (500 μM; 48 hours) in skin fibroblasts from patients with CS (n = 3). (G) Stimulation of respiratory chain complex enzymatic activity in the hearts of CS mice treated with bezafibrate 0.05% in the diet (for 12 weeks). Effect of the bezafibrate 0.05% in Chow diet (CD + BZ 0.05%) on (H) left ventricle (LV) mass, (I) left ventricle volume, (J) heart mass, (K) heart beating rate, and (L) systolic arterial pressure after 12 weeks of treatment in CS mouse model (n = 9) as compared with untreated CS mice fed with chow diet (CD) (n = 9). One-way ANOVA with Dunnett’s correction for multiple testing was used to compare the 4 groups of cells (controls treated or untreated with bezafibrate and CS mice treated or untreated with bezafibrate). Unpaired t test was used to compare the 2 groups of mice (WT or Costello). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

A major impact of the LKB1/AMPK inhibition observed in the different CS models investigated in our study is the alteration of mitochondrial proteostasis, albeit with tissue-specific differences. The causality link between AMPK signaling and the control of mitochondrial proteostasis was established in previous studies (46, 55, 56). Our analysis of the molecular mechanisms underlying the alteration of mitochondrial proteome and bioenergetics in skin fibroblasts from patients with CS and CS mouse hearts showed the inhibition of key executors and regulators of mitochondrial turnover to be AMPK, SQSTM1/P62, and CRIF1. These proteins play a role in mitophagy, and biochemical studies have shown that AMPKα2 coordinates this process and thereby protects against heart failure (57, 58), in complete agreement with our findings. Mechanistically, we observed a tissue-specific alteration in the machinery responsible for mitochondrial proteostasis, a very complex and intricate network of quality and quantity control mechanisms (59) recently considered as a therapeutic target in myocardial infarction (60). In the CS cell models, we further observed the altered expression of the autophagy regulators (ATG7) and targeted mitochondrial degradation (CLPX) but also that of central mediators of mitochondrial biogenesis (such as TFAM), suggesting defective mitochondrial proteostasis and biogenesis in cells from patients with CS. Our hypothesis was confirmed by the observation of reduced autophagic flux in cells from patients with CS, accumulation of mitochondrial proteins, and defective organelle bioenergetics. The mitochondrial protein CLPX reduced in cells from patients with CS is the ATP-dependent Clp protease ATP-binding subunit. The ClpP-ClpX (CLpXP) complex is a central regulator of mitochondrial proteostasis and bioenergetics (27, 28, 61, 62). Our observation of CLPX downregulation by mutant HRAS in CS could suggest further study of the link between the RAS/MAPK pathway and CLPXP.

The variable alteration of the mitochondrial proteostasis machinery and of the mitochondrial proteome itself, observed between the different tissues of the CS mouse, raised the question of the tissue-specific impact of HRAS germline mutations. There are still questions regarding the degree of functional tissue specificity exhibited by mutant HRAS in various cell types and tissues, and previous studies have shown that germline HRAS mutation alters the development of the different tissues to variable extents (63). For instance, the developmental phenotypes of patients with CS and CS animal models indicate a strong tissue-specific effect of the germline HRAS mutations on the craniofacial development, heart structure and function, skin, and predisposition to specific cancers. This tissue-specific impact of HRAS germline mutations was partly explained by the specific role of the different RAS isoforms in tissues of variable embryological origins (64, 65). Differences in the interactions with regulators and effectors of the RAS signaling pathway also participate to the tissue-specific functions of the different RAS isoforms. The LKB1/AMPK signaling involved in CS molecular pathophysiology is also a tissue-specific pathway (58, 66, 67). In particular, the control of mitochondrial biogenesis and degradation by AMPK is variable between tissues. We measured a reduced TFAM content in HRAS mutant cell models and in the CS mouse heart. However, the reduction in PGC1α was only detected in the mutant HRAS cell models. This result could be explained by the fact that PGC1α is typically regulated by deacetylation in muscle, rather than through changes in expression (68). Another tissue-specific concern of our study was the use of skin fibroblasts that present with very different bioenergetic features as compared with cardiomyocytes. Previous studies in the field of mitochondrial diseases have shown that skin fibroblasts do not recapitulate the bioenergetic dysfunction found in the skeletal muscle (69). The use of hiPSC-CMs and of CS mouse hearts was instrumental to validating our findings. In particular, we found that most of the ATP produced in CS hiPSC-CMs was obtained from glycolysis, as previously observed in conditions of cardiac disease and OXPHOS dysfunction (70, 71). However, in the context of CS, the skin fibroblasts constitute a relevant cell model, as the skin expresses the disease in various forms (72). Conversely, while hiPSC-CMs from patients with CS provide a pertinent model allowing comparison with CS mouse hearts and human hearts, the growth conditions of the cardiomyocytes will directly impact their bioenergetics and may not provide the best environment to study the mechanism underlying OXPHOS alteration. In particular, the medium used for the maintenance of hiPSC-CMs contains a large number of growth factors and high concentrations of energy substrates, which limits the study of the LKB1/AMPK pathway. To conclude, we think that studying the mechanisms in the CS mouse heart may provide a more reliable data set for understanding the pathophysiology of CS cardiac disease; the cell models used in our study, which all revealed a constitutive mitochondrial dysfunction, present specific bias for the mechanistic investigations. Moreover, our discovery of altered LKB1/AMPK signaling
Figure 8. Combination of bezafibrate and urolithin A restores normal phenotype in Costello zebrafish. Phenotype analysis of (A) control zebrafish or (B–H) Costello zebrafish injected with HRASV12 plasmid at 5 dpf, after 4 days of treatment with (B) DMSO, (C) bezafibrate, (D) urolithin A, or (E and F) bezafibrate (BZ) and urolithin A (UA) in combination. Costello zebrafish developed edema (B–D, arrows) or hemorrhages and vascularization defects (B and D, asterisks). (F) Treatment with a combination of 10 μM BZ and 5 μM UA markedly reduced the percentage of abnormal embryos. (G) Illustration of the phenotypes observed in Costello zebrafish at 5 dpf after expression of HRASV12 plasmid. (H) Expression level of the mitochondrial protein TOM20 in control or HRAS p.G12V embryos. TOM20 protein content determined by Western blot was normalized to the total protein content. (I) Survival rate of Costello zebrafish after 4 days of treatment with DMSO, bezafibrate, or UA alone or in combination. Data were normalized to day 1 of treatment. (J) Percentage of defect appearance in Costello zebrafish after 4 days of treatment with DMSO, bezafibrate, or UA alone or in combination. Data are expressed as number of embryos or as the mean value of TOM20 expression. Unpaired t test was used to compare the 2 groups of zebrafish (WT or Costello). *P < 0.05.
and defective mitochondrial proteostasis and bioenergetics only explains one facet of the complexity of CS molecular pathophysiology. For instance, Prkaa2-KO mice show no cardiac alteration, and these mice show exacerbated pressure overload–induced left ventricular hypertrophy only under stress conditions (73). Likewise, we found a small activation of AMPKα2 (p-thr172) and a consequent low inhibition of ACC (p-ser79) in the CS mouse and cell models investigated under routine conditions.

In this study, we discovered a reduction of LKB1 protein content in CS mouse hearts and skin fibroblasts from patients with CS; this is in agreement with results from a previously published work that showed that genetic deletion of LKB1 in the heart triggers hypertrophy and cardiac dysfunction (74). These findings suggest that AMPK inhibition alone cannot induce heart dysfunction and that additional stress, as mediated by the deregulated HRAS/MAPK pathway, or a challenging bioenergetic environment must occur. A series of transcriptomic targets have been identified in response to AMPK activation. For instance, AMPK was shown to phosphorylate the transcription factor FoxO3 on 6 serine residues to enhance its transcriptional activity (75) toward its target genes. Growing evidence suggests that in the long-term AMPK promotes metabolic reprogramming via effects on gene expression at least partly through regulation of specific transcription factors and transcriptional coactivators (31). In agreement with this view, analysis of CS heart proteome revealed a complex molecular signature of cardiac dilation and damage, apparently independent of AMPK signaling. Finally, previous metabolic investigation in a HRAS p.G12S CS mouse model (10) revealed a decrease in fatty acid oxidation enzyme expression in the liver, in agreement with the inhibition of LKB1/AMPK signaling observed in our study.

Finally, our work demonstrated that BZ could rescue or prevent the defective mitochondrial function in skin fibroblasts from patients with CS and CS mouse hearts. We discovered that the mode of action of BZ in vitro is multiple and involves the stimulation of PGC1α expression, mTOR inhibition, and activation of LC3II-mediated autophagy. In particular, BZ rescued the level of the mitochondrial proteostasis regulator ClpX, which was downregulated in CS mouse hearts and cell models. We treated the CS mouse with 0.05% BZ in the diet based on a study showing cardiac beneficial effects in a mouse model of the mitochondrial disease Barth syndrome (42). Other rodent studies using a higher dose of BZ also showed OXPHOS improvement and beneficial effects in various mouse models with mitochondrial dysfunction (40, 76–81). However, hepatomegaly was observed when using suprapharmacological doses of BZ in mice, although this effect was not observed in humans (40). BZ is well tolerated in humans, and clinical trials have revealed that this drug can reduce the heart rate and blood pressure in patients with hypertriglyceridemia (82). BZ also improved the condition of patients with hyperlipidemia (83) and fatty oxidation defect (41). Furthermore, a recent trial on 6 patients with a genetic mitochondrial disease revealed an improved cardiac function (84). To further evaluate the potential of mitochondrial bioenergetics and proteostasis modulation in the treatment of CS in the early stage of the disease we tested the efficacy UA alone or in combination with BZ in a previously described CS zebrafish model (45). The mitochondrial proteostasis modulator UA was recently characterized and showed no toxicity in a human clinical trial (85–87). We discovered that UA in combination with BZ synergistically increased the survival of CS embryos and significantly reduced the occurrence of developmental defects. The mode of action of this combination of drugs involved the stimulation of fatty acid oxidation, the activation of several mitochondrial proteostasis regulators and executors, and the stimulation of the acute-phase response, which involved regulation of the angiotensin system. Of interest for our study, previous work showed that AMPK regulates the renin-angiotensin system, and the observed alteration of AMPK signaling in CS could also participate in the cardiac disease through this system (88).

Therefore, our study provides preclinical and molecular evidence that stimulation of mitochondrial quantity control and bioenergetics, as obtained with BZ and UA treatment, improved the health of cellular and animal models of CS. A more detailed heart structure and function analysis with additional clinically relevant data will be required before the use of BZ and UA in combination for the prevention of cardiac disease in CS is proposed. To conclude, our work supports the view that mitochondrial quality surveillance is a therapeutic target in heart dysfunction in CS.

Methods

Further information can be found in Supplemental Methods.

Study approval. All patients gave written informed consent to participate in this study, according to the Committee for the Protection of Persons (University of Bordeaux, Bordeaux, France) (IDRCB no. 2015-A00705-44, CPP 2014/44, ClinicalTrials.gov NCT02812511). All the zebrafish studies conducted for this manuscript have been reviewed and approved by the Comité d’éthique Langedoc Roussillon (Université de Montpellier, Montpellier, France) (F341725/21063-2019061317218694). The mouse preclinical studies were performed in accordance with the European guidelines for animal experimentation at the Institut Clinique de la Souris, Illkirch-Graffenstaden, France. All the mouse studies conducted for this manuscript have been reviewed and approved by the comité d’ethique Com’Eth, Illkirch, France.

Author contributions

RR, CH, TS, and LD participated in the conception and design of the study. LD and CH (gene and miR expression studies); LD, NDA, and NB (patients with CS and mutant HRAS bioenergetics properties); ED (respiratory chain enzymes activities); GBA, YH, and TS (BZ preclinical study on the CS mouse model); and CA and WB (proteomics) performed the experiments. RR and LD performed bioinformatics (IPA, Qiagen) and statistical (Prism) analyses of the data. VGP produced the lentiviral plasmid for HRAS mutant ectopic expression. PE participated in the bioenergetics analyses. SC and MB provided expertise in proteomics. PES and JBT performed the cardiology investigations on patients with CS. LF and KK performed the zebrafish study at Azelead. FM, NL, MD, and LB produced the hiPSCs and their differentiation in cardiomyocytes. They also performed Western blotting on these cells. DL performed diagnostics studies, genetic identification, and patient management. DL, NB, and RR obtained the agreement to generate the cell lines from patients with CS used in this study (ClinicalTrials.gov NCT02812511). RR supervised the entire project and wrote the paper along with LD and NDA, with suggestions from all authors.
Acknowledgments

We are very grateful to the French Association of Costello Syndrome and Cardiofaciocutaneous Syndrome, which supported this study in two ways. This association informed patients with CS about the need for skin samples for research and funded the generation of the HRAS
g12S CS mouse model at the Mouse Clinical Institute (http://www.ics-mci.fr/en/) under the supervision of TS and YH. We are indebted to all the families of patients with CS who provided consent to allow us to perform skin biopsies on their children. We thank the children with CS and Cardiofaciocutaneous Syndrome who participated in this study for their efforts and dedication to this project. We are grateful to Marina Mione from the Department of Cellular, Computational and Integrative Biology, University of Trento, for providing the GFP-H-RASV12 plasmid used to generate the CS zebrafish model. We also thank Marie-Laure Martin-Négrier from the Department of Anatomopathology of Bordeaux hospital for her help in the histo-enzymologic study of CS mouse muscle. We thank Fatima Djouadi and Jean Bastin for discussions on BZ’s mode of action. We acknowledge funding by the French National Research Agency (ANR) through the COSMIT program (pathophysiology of CS, ANR-15-CE17-0003). Our project was also supported by funding from the Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Bordeaux. Development of the drug combination BZ-UA is supported by SATT Nouvelle-Aquitaine “AST.” We are grateful to our funders for providing support these last years.

Address Correspondence: Rodrigue Rossignol, INSERM U1211, MRGM Laboratory, Bordeaux University Hospital (CHU), place amélie Raba-Léon 33000 Bordeaux, France. Phone: 33.0.5.57.82.10.54; Email rodrigue.rossignol@u-bordeaux.fr.
specific evolutionary patterns of miRNAs. Nucleic Acids Res. 2012;40(13):5890–900.
55. Lagoue M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;126(7):1109–1122.
56. Pengo N, et al. A reversible phospho-switch mediated by ULK1 regulates the activity of autophagy protease ATG4B. Nat Commun. 2017;8(1):294.
57. Wang B, et al. AMPK2 protects against the development of heart failure by enhancing mitophagy via PINK1 phosphorylation. Circ Res. 2018;122(5):712–729.
58. Drake JC, et al. Mitochondria-localized AMPK responds to local energetics and contributes to exercise and energy-stressed-induced mitophagy. Proc Natl Acad Sci U S A. 2021;118(37):e2025932118.
59. Song J, et al. Quality control of the mitochondrial proteome. Nat Rev Mol Cell Biol. 2021;22(1):54–70.
60. Zhu H, et al. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction. Acta Physiol (Oxf). 2021;231(3):e13590.
61. Ishizawa J, et al. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 2019;35(5):721–737.
62. Kasashima K, et al. Maintenance of mitochondrial genome distribution by mitochondrial AAA+ protein ClpX. Exp Cell Res. 2012;318(18):2335–2343.
63. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216–231.
64. Esteban LM, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21(5):1444–1452.
65. Newlayczuk AU, et al. Quantification of spatiotemporal patterns of Ras isoform expression during development. Sci Rep. 2017;7:41297.
66. Ugbari M, et al. AMPK modulates tissue and organ ischemic aging in a non-cell-autonomous manner. Cell Rep. 2014;8(6):1767–1780.
67. Viollet B, et al. AMPK: lessons from transgenic and knockout animals. Front Biosci. 2009;14(1):19–44.
68. Cánto C, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010;11(3):213–219.
69. Danhelková T, et al. Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. BMC Pediatr. 2020(21):1.
70. Fukuda R, et al. Stimulation of glycolysis promotes cardiomyocyte proliferation after injury in adult zebrafish. EMBO Rep. 2020;21(8):e49752.
71. Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc. 2019;8(12):e012673.
72. Morice-Picard F, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol. 2013;30(6):665–673.
73. Zhang P, et al. AMP activated protein kinase-ε2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension. 2008;52(5):918–924.
74. Ikeda Y, et al. Cardiac-specific deletion of LKB1 leads to hyperthyroidism and dysfunction. J Biol Chem. 2009;284(51):35839–35849.
75. Greer EL, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007;282(41):30107–30119.
76. Johri A, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet. 2012;21(5):1124–1137.
77. Dumont M, et al. Beázifibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet. 2012;21(23):5091–5105.
78. Viscomi C, et al. In vivo correction of COX deficiency by activation of the AMPK/PKG-1α axis. Cell Metab. 2011;14(1):80–90.
79. Dillon LM, et al. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS One. 2012;7(9):e44335.
80. Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet. 2012;21(5):526–535.
81. Nakajima T, et al. Beázifibrate at clinically relevant doses decreases serum/urine triglycerides via down-regulation of sterol regulatory element-binding protein-4c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol. 2009;75(4):782–792.
82. Jonkers IJ, et al. Beázifibrate reduces heart rate and blood pressure in patients with hypertosphism. J Hypertension. 2001;19(4):749–755.
83. Bonnefont JP, et al. L-NAME-induced increase after mitochondrial disorders. Proc Natl Acad Sci U S A. 2021;118(37):e2025932118.
84. Steele H, et al. Metabolic effects of bezafibrate treatment in patients with the myopathic phenotype. Mol Pharmacol. 2009;75(4):782–792.
85. Verjans R, et al. Comparative analysis of human and mouse expression data illuminates tissue-specific evolutionary patterns of miRNAs. Nucleic Acids Res. 2012;40(13):5890–900.
55. Lagoue M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;126(7):1109–1122.
56. Pengo N, et al. A reversible phospho-switch mediated by ULK1 regulates the activity of autophagy protease ATG4B. Nat Commun. 2017;8(1):294.
57. Wang B, et al. AMPK2 protects against the development of heart failure by enhancing mitophagy via PINK1 phosphorylation. Circ Res. 2018;122(5):712–729.
58. Drake JC, et al. Mitochondria-localized AMPK responds to local energetics and contributes to exercise and energy-stressed-induced mitophagy. Proc Natl Acad Sci U S A. 2021;118(37):e2025932118.
59. Song J, et al. Quality control of the mitochondrial proteome. Nat Rev Mol Cell Biol. 2021;22(1):54–70.
60. Zhu H, et al. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction. Acta Physiol (Oxf). 2021;231(3):e13590.
61. Ishizawa J, et al. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 2019;35(5):721–737.
62. Kasashima K, et al. Maintenance of mitochondrial genome distribution by mitochondrial AAA+ protein ClpX. Exp Cell Res. 2012;318(18):2335–2343.
63. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216–231.
64. Esteban LM, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21(5):1444–1452.
65. Newlayczuk AU, et al. Quantification of spatiotemporal patterns of Ras isoform expression during development. Sci Rep. 2017;7:41297.
66. Ugbari M, et al. AMPK modulates tissue and organ ischemic aging in a non-cell-autonomous manner. Cell Rep. 2014;8(6):1767–1780.
67. Viollet B, et al. AMPK: lessons from transgenic and knockout animals. Front Biosci. 2009;14(1):19–44.
68. Cánto C, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010;11(3):213–219.
69. Danhelková T, et al. Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. BMC Pediatr. 2020(21):1.
70. Fukuda R, et al. Stimulation of glycolysis promotes cardiomyocyte proliferation after injury in adult zebrafish. EMBO Rep. 2020;21(8):e49752.
71. Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc. 2019;8(12):e012673.
72. Morice-Picard F, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol. 2013;30(6):665–673.